Belzutifan (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Belzutifan" in English language version.

refsWebsite

Global rank English rank

15web.archive.org

1^st place

12nih.gov

4^th place

6doi.org

2^nd place

3tga.gov.au

3,984^th place

2,622^nd place

3semanticscholar.org

11^th place

8^th place

3fda.gov

447^th place

338^th place

2businesswire.com

615^th place

407^th place

2europa.eu

68^th place

117^th place

2hres.ca

low place

1hpfb-dgpsa.ca

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1sps.nhs.uk

low place

1cancernetwork.com

low place

1gov.uk

432^nd place

278^th place

1raps.org

low place

businesswire.com

"Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482)" (Press release). Merck. 16 March 2016. Archived from the original on 18 March 2021. Retrieved 25 April 2021 – via Business Wire.
"FDA Approves Merck's Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor Welireg (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors" (Press release). Merck. 13 August 2021. Archived from the original on 13 August 2021. Retrieved 13 August 2021 – via Business Wire.

cancernetwork.com

"FDA Grants Priority Review to Belzutifan for von Hippel-Lindau Disease–Associated RCC". Cancer Network. 16 March 2021. Archived from the original on 26 April 2021. Retrieved 26 April 2021.

doi.org

Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. (May 2021). "Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis". Nature Medicine. 27 (5): 802–805. doi:10.1038/s41591-021-01324-7. PMC 9128828. PMID 33888901. S2CID 233371559.
Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. (May 2021). "Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis". Nature Medicine. 27 (5): 802–805. doi:10.1038/s41591-021-01324-7. PMC 9128828. PMID 33888901.
Kamihara J, Hamilton KV, Pollard JA, Clinton CM, Madden JA, Lin J, et al. (November 2021). "Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome". The New England Journal of Medicine. 385 (22): 2059–2065. doi:10.1056/NEJMoa2110051. PMC 11245359. PMID 34818480. S2CID 244651726.
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. (November 2021). "Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease". The New England Journal of Medicine. 385 (22): 2036–2046. doi:10.1056/NEJMoa2103425. PMC 9275515. PMID 34818478.
Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, et al. (November 2022). "FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors". Clinical Cancer Research. 28 (22): 4843–4848. doi:10.1158/1078-0432.CCR-22-1054. PMC 9669093. PMID 35727604.
Deeks ED (November 2021). "Belzutifan: First Approval". Drugs. 81 (16): 1921–1927. doi:10.1007/s40265-021-01606-x. PMID 34613603. S2CID 238360443.

europa.eu

ema.europa.eu

"Welireg EPAR". European Medicines Agency (EMA). 12 December 2024. Retrieved 16 December 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"First medicine to treat rare genetic disorder causing cysts and tumors". European Medicines Agency (EMA) (Press release). 13 December 2024. Retrieved 16 December 2024.

fda.gov

"FDA approves belzutifan for cancers associated with von Hippel-Lindau". U.S. Food and Drug Administration (FDA). 13 August 2021. Archived from the original on 13 August 2021. Retrieved 13 August 2021. This article incorporates text from this source, which is in the public domain.
Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

gov.uk

"First Innovation Passport awarded to help support development and access to cutting-edge medicines". Medicines and Healthcare products Regulatory Agency (MHRA) (Press release). 26 February 2021. Archived from the original on 14 August 2021. Retrieved 14 August 2021.

hpfb-dgpsa.ca

dhpp.hpfb-dgpsa.ca

"Details for: Welireg". Health Canada. 1 September 2022. Archived from the original on 3 March 2024. Retrieved 3 March 2024.

hres.ca

pdf.hres.ca

"Welireg (belzutifan) Product monograph" (PDF). Health Canada. Archived (PDF) from the original on 28 October 2022. Retrieved 1 October 2022.

hpr-rps.hres.ca

"Summary Basis of Decision - Welireg". Health Canada. 23 October 2014. Archived from the original on 24 February 2023. Retrieved 23 February 2023.

medicines.org.uk

"Welireg SmPC". (emc). 16 January 2024. Retrieved 16 December 2024.

nih.gov

pubmed.ncbi.nlm.nih.gov

Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. (May 2021). "Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis". Nature Medicine. 27 (5): 802–805. doi:10.1038/s41591-021-01324-7. PMC 9128828. PMID 33888901. S2CID 233371559.
Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. (May 2021). "Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis". Nature Medicine. 27 (5): 802–805. doi:10.1038/s41591-021-01324-7. PMC 9128828. PMID 33888901.
Kamihara J, Hamilton KV, Pollard JA, Clinton CM, Madden JA, Lin J, et al. (November 2021). "Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome". The New England Journal of Medicine. 385 (22): 2059–2065. doi:10.1056/NEJMoa2110051. PMC 11245359. PMID 34818480. S2CID 244651726.
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. (November 2021). "Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease". The New England Journal of Medicine. 385 (22): 2036–2046. doi:10.1056/NEJMoa2103425. PMC 9275515. PMID 34818478.
Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, et al. (November 2022). "FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors". Clinical Cancer Research. 28 (22): 4843–4848. doi:10.1158/1078-0432.CCR-22-1054. PMC 9669093. PMID 35727604.
Deeks ED (November 2021). "Belzutifan: First Approval". Drugs. 81 (16): 1921–1927. doi:10.1007/s40265-021-01606-x. PMID 34613603. S2CID 238360443.

ncbi.nlm.nih.gov

Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. (May 2021). "Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis". Nature Medicine. 27 (5): 802–805. doi:10.1038/s41591-021-01324-7. PMC 9128828. PMID 33888901. S2CID 233371559.
Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. (May 2021). "Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis". Nature Medicine. 27 (5): 802–805. doi:10.1038/s41591-021-01324-7. PMC 9128828. PMID 33888901.
Kamihara J, Hamilton KV, Pollard JA, Clinton CM, Madden JA, Lin J, et al. (November 2021). "Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome". The New England Journal of Medicine. 385 (22): 2059–2065. doi:10.1056/NEJMoa2110051. PMC 11245359. PMID 34818480. S2CID 244651726.
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. (November 2021). "Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease". The New England Journal of Medicine. 385 (22): 2036–2046. doi:10.1056/NEJMoa2103425. PMC 9275515. PMID 34818478.
Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, et al. (November 2022). "FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors". Clinical Cancer Research. 28 (22): 4843–4848. doi:10.1158/1078-0432.CCR-22-1054. PMC 9669093. PMID 35727604.

dailymed.nlm.nih.gov

"Welireg- belzutifan tablet, film coated". DailyMed. Archived from the original on 28 October 2022. Retrieved 12 September 2021.

raps.org

"MHRA awards first 'innovation passport' under new pathway". RAPS (Press release). Archived from the original on 26 April 2021. Retrieved 25 April 2021.

semanticscholar.org

api.semanticscholar.org

Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. (May 2021). "Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis". Nature Medicine. 27 (5): 802–805. doi:10.1038/s41591-021-01324-7. PMC 9128828. PMID 33888901. S2CID 233371559.
Kamihara J, Hamilton KV, Pollard JA, Clinton CM, Madden JA, Lin J, et al. (November 2021). "Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome". The New England Journal of Medicine. 385 (22): 2059–2065. doi:10.1056/NEJMoa2110051. PMC 11245359. PMID 34818480. S2CID 244651726.
Deeks ED (November 2021). "Belzutifan: First Approval". Drugs. 81 (16): 1921–1927. doi:10.1007/s40265-021-01606-x. PMID 34613603. S2CID 238360443.

sps.nhs.uk

"Belzutifan". SPS - Specialist Pharmacy Service. 18 March 2021. Archived from the original on 26 April 2021. Retrieved 25 April 2021.

tga.gov.au

"Welireg". Therapeutic Goods Administration (TGA). 4 January 2023. Archived from the original on 5 January 2023. Retrieved 6 January 2023.
"Welireg (Merck Sharp & Dohme (Australia) Pty Ltd)". Therapeutic Goods Administration (TGA). 13 January 2023. Archived from the original on 27 March 2023. Retrieved 8 April 2023.
"Welireg belzutifan 40 mg film-coated tablet bottle (355338)". Therapeutic Goods Administration (TGA). 23 December 2022. Archived from the original on 8 April 2023. Retrieved 8 April 2023.

web.archive.org

"Welireg". Therapeutic Goods Administration (TGA). 4 January 2023. Archived from the original on 5 January 2023. Retrieved 6 January 2023.
"Welireg (Merck Sharp & Dohme (Australia) Pty Ltd)". Therapeutic Goods Administration (TGA). 13 January 2023. Archived from the original on 27 March 2023. Retrieved 8 April 2023.
"Welireg belzutifan 40 mg film-coated tablet bottle (355338)". Therapeutic Goods Administration (TGA). 23 December 2022. Archived from the original on 8 April 2023. Retrieved 8 April 2023.
"Welireg (belzutifan) Product monograph" (PDF). Health Canada. Archived (PDF) from the original on 28 October 2022. Retrieved 1 October 2022.
"Summary Basis of Decision - Welireg". Health Canada. 23 October 2014. Archived from the original on 24 February 2023. Retrieved 23 February 2023.
"Details for: Welireg". Health Canada. 1 September 2022. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
"Welireg- belzutifan tablet, film coated". DailyMed. Archived from the original on 28 October 2022. Retrieved 12 September 2021.
"FDA approves belzutifan for cancers associated with von Hippel-Lindau". U.S. Food and Drug Administration (FDA). 13 August 2021. Archived from the original on 13 August 2021. Retrieved 13 August 2021. This article incorporates text from this source, which is in the public domain.
"Belzutifan". SPS - Specialist Pharmacy Service. 18 March 2021. Archived from the original on 26 April 2021. Retrieved 25 April 2021.
"Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482)" (Press release). Merck. 16 March 2016. Archived from the original on 18 March 2021. Retrieved 25 April 2021 – via Business Wire.
"FDA Grants Priority Review to Belzutifan for von Hippel-Lindau Disease–Associated RCC". Cancer Network. 16 March 2021. Archived from the original on 26 April 2021. Retrieved 26 April 2021.
"FDA Approves Merck's Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor Welireg (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors" (Press release). Merck. 13 August 2021. Archived from the original on 13 August 2021. Retrieved 13 August 2021 – via Business Wire.
Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
"First Innovation Passport awarded to help support development and access to cutting-edge medicines". Medicines and Healthcare products Regulatory Agency (MHRA) (Press release). 26 February 2021. Archived from the original on 14 August 2021. Retrieved 14 August 2021.
"MHRA awards first 'innovation passport' under new pathway". RAPS (Press release). Archived from the original on 26 April 2021. Retrieved 25 April 2021.